Press Releases

Application A pproval Will Further Extend Current Operating Runway to Over Three Years To date, through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program ,   Celsion has r aised over $14 million in N on- D ilutive C apital LAWRENCEVILLE, N.J. , Nov.

Chief Science Officer Dr. Khursheed Anwer to also Participate in Two Panel Discussions LAWRENCEVILLE, N.J. , Nov. 08, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announces that

Chief Science Officer Dr. Khursheed Anwer to D eliver V irtual   P resentation Monday, October 18 at 7:30 a.m. Eastern Time LAWRENCEVILLE, N.J. , Oct. 15, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA mediated immunotherapy and

Chief Science Officer Dr. Khursheed Anwer to D eliver V irtual   P resentation on Celsion’s O ngoing W ork with DNA-based V accines LAWRENCEVILLE, N.J. , Oct. 12, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA mediated immunotherapy

Investigator-Sponsored Research with ThermoDox ®   Continues in Multiple Indications New Support for ThermoDox ® ’s P otential from the National Institutes of Health under a Cooperative Research and Development Agreement ZUG, Switzerland , Oct. 11, 2021 (GLOBE NEWSWIRE) -- Celsion   GmbH , a wholly

LAWRENCEVILLE, N.J. , Oct. 05, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announces the strengthening of its management team with a new hire and a promotion in its vaccine

LAWRENCEVILLE, N.J. , Sept. 30, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that management will present at the following investment conferences in October: Chardan’s 5 th

  E xpands GEN-1 P rogram C ollaboration to Add   C linical and C ommercial B atches of I nvestigational V accine LAWRENCEVILLE, N.J. and HAINAN, China , Sept. 17, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN ) , a clinical-stage company focused on DNA-based immunotherapy and

Results Indicate Induction of Adaptive Immune Response Against SARS-CoV-2 Company Plans Additional Development Work to Further Optimize its Vaccine Platform Through Vector Compositions, Delivery Route, Dosing and Dosing Frequency, and Use of Molecular Adjuvant LAWRENCEVILLE, N.J. , Sept.

Strong Balance Sheet Supports Focus i n Immuno-Oncology and on   Next-Generation Vaccine Initiative Conference Call Begins Today   at 11:00 a.m.   Eastern Time LAWRENCEVILLE, N.J. , Aug. 12, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical-stage drug-development company